Conclusion of Non-Exclusive Agreements for Pharmaceuticals Containing Ponesimod (ATC Code: L04AE04) via an Open-House Model
About This Opportunity
TranslatedThis tender concerns the establishment of non-exclusive agreements for the supply of pharmaceuticals containing the active ingredient Ponesimod, identified by the ATC code L04AE04. The procurement process will operate under an 'open-house' model, which typically allows additional suppliers to join an existing framework agreement during its term, provided they meet the stipulated criteria. This approach aims to ensure a competitive and flexible supply chain for this specific medication.
The contracting authority is seeking to secure reliable access to Ponesimod, a drug used in the treatment of certain medical conditions. While the detailed description is referenced as 'Kurzbeschreibung' (short description), the core objective is to enter into agreements that facilitate the procurement of this pharmaceutical product. The non-exclusive nature of the agreements means that the contracting authority is not restricted to a single supplier and can contract with multiple providers who successfully apply under the open-house model.
Key requirements for potential suppliers are expected to include the ability to provide pharmaceuticals meeting specific quality standards, adherence to regulatory requirements for medicinal products, and potentially the capacity to meet demand fluctuations. The open-house model suggests a streamlined application process for interested parties to join the agreement post-initial award. Further details regarding the specific scope, duration, eligibility criteria, and submission deadlines would be available in the full tender documentation. This initiative is crucial for ensuring the availability of Ponesimod for its intended therapeutic uses.
This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals. Located in Germany, Europe, this opportunity is open to firms and consortiums. Proposals must be submitted before April 30, 2027.
Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. Interested parties should review the full documentation on the original source before submitting their proposal.
Description
Original language: GermanThis tender, originating from Germany and published on the TED (Tenders Electronic Daily) platform, seeks to establish non-exclusive framework agreements for the procurement of medicinal products containing the active pharmaceutical ingredient Ponesimod (ATC code: L04AE04). The contracting authority, managed by the Publications Office of the European Union, is looking to implement an "open-house" model for this procurement.
This procurement approach signifies an ongoing opportunity for eligible suppliers to join the framework agreement throughout its duration, rather than a one-time award. The objective is to secure a reliable and competitive supply of Ponesimod, a medication typically used in the treatment of specific immunological conditions. Interested parties are invited to submit proposals detailing their capability to supply this pharmaceutical.
Typical requirements for such tenders often include demonstrating adherence to Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP), providing comprehensive product information, including pharmacopoeial compliance and stability data, and presenting robust quality management systems. Suppliers will likely need to outline their production capacity, supply chain reliability, and commitment to regulatory standards. The open-house nature of this tender suggests a structured process for onboarding new suppliers who meet the established criteria, ensuring continuous access to this important therapeutic agent for the German healthcare market.
Data provenance
This notice is sourced from TED - Tenders Electronic Daily (EU) and was originally published on March 9, 2026. Last refreshed 5 days ago. Original language: German. BidsFactory mirrors official procurement notices and links back to the source for full legal text.
About AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen
AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen has issued 36 procurement notices on BidsFactory, including 30 currently open and 2 awarded contracts. Activity concentrates in Health & Medical, General Supplies & Services, and Water & Sanitation. All notices are published for Germany. Notices are distributed via TED - Tenders Electronic Daily (EU) and DÖE Bekanntmachungsservice (Germany). Most recent publication: June 9, 2026.
Frequently asked questions about this tender
How can I submit a bid?
Visit TED - Tenders Electronic Daily (EU) to access the full notice, required documents, and submission instructions provided by the contracting authority.
When does this tender close?
The submission deadline is April 30, 2027. You have 308 days left to prepare and submit your proposal to the contracting authority.
Who is the contracting authority?
This notice was issued by AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen in Germany. The authority is responsible for evaluating bids, awarding the contract, and managing performance.
What type of contract is this?
This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.
Where will the contract be performed?
The contract is for delivery in Germany. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.
Find tenders like this automatically
Set up alerts and filters that match your business — never miss a relevant opportunity again.